Dualitas Therapeutics secured $65 million in Series A funding to advance its bispecific antibody platform targeting two immune cell surface proteins simultaneously. This proximity biology approach aims to enhance modulation of immune pathways in autoimmune and inflammatory diseases. Investors include Eli Lilly and Chugai Pharmaceutical among others, highlighting confidence in this innovative immune therapy approach. Dualitas is positioned to explore novel target combinations to improve treatment efficacy beyond monoclonal antibodies.